Lazcluze (lazertinib) — Highmark

Initial criteria

• age ≥ 18 years
• Diagnosis of locally advanced or metastatic NSCLC (ICD‑10: C34) AND disease harbors EGFR exon 19 deletion OR EGFR exon 21 (L858R) substitution mutation (as determined by an FDA‑approved test)
• Member is treatment‑naïve for advanced disease
• Lazcluze will be administered in combination with Rybrevant